The Syringe Driver: Continuous subcutaneous infusions in palliative care
Description:
The syringe driver is a simple and cost-effective method of delivering a continuous subcutaneous infusion (CSCI). A CSCI provides a safe and effective way of drug administration and can be used to maintain symptom control in patients who are no longer able to take oral medication.
There have been several developments in this field since the second edition of this highly successful book. The text in this edition has been completely revised, incorporating new treatment options and an extensive list of new compatibility data.
This book serves as a valuable reference source, providing comprehensive review of syringe driver use and administration of drugs via CSCI. The first chapter provides an overview of syringe drivers and CSCIs, including a useful array of frequently asked questions. The second chapter provides revised and referenced information relating to most drugs likely to be administered via a CSCI using a syringe driver. The third chapter discusses the control of specific symptoms that are often encountered when CSCIs are required. The fourth and final chapter contains an extensive, referenced list of physical and chemical stability data relating to drug combinations administered via CSCI.
Best prices to buy, sell, or rent ISBN 9780199569724
Frequently Asked Questions about The Syringe Driver: Continuous subcutaneous infusions in palliative care
The price for the book starts from $10.05 on Amazon and is available from 6 sellers at the moment.
If you’re interested in selling back the The Syringe Driver: Continuous subcutaneous infusions in palliative care book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the The Syringe Driver: Continuous subcutaneous infusions in palliative care book, the best buyback offer comes from and is $ for the book in good condition.
Not enough insights yet.
Not enough insights yet.